Trial · NCT06856499
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
NCT06856499, Phase 1, Recruiting, University of Colorado, Denver
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer. Trials, record NCT06856499. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06856499
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
- NCT number
- NCT06856499
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 50 participants, estimated
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Cirtuvivint, Olaparib
- First posted
- 2025-03-04
- Last updated
- 2026-07-24
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Determine the Safety of Combination Cirtuvivint with Olaparib | 6 months | To determine the safety and tolerability of combination Cirtuvivint and Olaparib in BRCA/HRD platinum resistant ovarian cancer as evaluated by CTCAE v5.0 criteria. |
| Primary | Determine the recommended Phase 2 Dose of Cirtuvivint with Olaparib | 6 months | To determine the recommended Phase 2 Dose (RP2D) and regimen of the combination therapy |
| Secondary | Evaluate the Cmax (peak plasma concentration) of Cirtuvivint when given in combination with olaparib | 3 years | To evaluate the Cmax (peak plasma concentration) of Cirtuvivint when given in combination with olaparib |
| Secondary | Evaluate the AUC (Area under the curve for plasma concentration) of Cirtuvivint when given in combination with olaparib | 3 years | To evaluate the AUC (Area under the curve for plasma concentration) of Cirtuvivint when given in combination with olaparib |
| Secondary | Evaluate the half-life (elimination half-life in plasma) of Cirtuvivint when given in combination with olaparib | 3 years | To evaluate the half-life (elimination half-life in plasma) of Cirtuvivint when given in combination with olaparib |
| Secondary | Evaluate CL (drug clearance) of Cirtuvivint when given in combination with olaparib | 3 years | To evaluate CL (drug clearance) of Cirtuvivint when given in combination with olaparib |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01CA288651 | Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer | CORR, BRADLEY | UNIVERSITY OF COLORADO DENVER | NATIONAL CANCER INSTITUTE | 2024 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06856499
GET https://conductscience.org/api/trials/v1/NCT06856499/registered